SUMMARY Plasmaandtissueinterleukin-2 receptor (IL-2R) levels weredetermined inpatients withactive ulcerative colitis andCrohn's disease. Compared withhealthy controls (median 440U/ml; range 240900), significantly higher levels ofplasma IL-2Rwerepresent inpatients withactive ulcerative colitis (median 1180U/ml; range580-7150; P< 0-002) andCrohn's disease (median 1340U/ml; range4809000; P< 0002). Compared withother laboratory parameters, plasma IL-2Rlevels wererelated most closely toclinical scoreofdisease activity inCrohn's disease. PlasmaIL-2Rlevels alsoreflected the clinical courseandmay provide a more accurate assessment ofdisease activity inCrohn's disease. In plasma ofpatients undergoing intestinal resection ofactive inflammatory boweldisease, raised levels ofIL-2Rwerepresent insamples frommesenteric vein(draining inflamed intestine) compared with those fromperipheral vein. Intissue homogenates ofcolonic biopsies, significantly higher levels of IL-2Rwere present inspecimens fromcolons withactive ulcerative colitis compared withhealthy controls (median 230-2, range20-7-581-5 versus779,range34-2-291 3;P<0-02).
[1]
GordonW. Duff.
PEPTIDE REGULATORY FACTORS IN NON-MALIGNANT DISEASE
,
1989,
The Lancet.
[2]
J. Symons,et al.
Soluble interleukin 2 receptor in atopic eczema.
,
1989,
BMJ.
[3]
I. Trowbridge.
Interleukin-2 receptor proteins
,
1987,
Nature.
[4]
J. Finke,et al.
Interleukin 2 activity of human intestinal mucosa mononuclear cells. Decreased levels in inflammatory bowel disease.
,
1984,
Gastroenterology.
[5]
J. Fermanian,et al.
Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index.
,
1981,
Gut.
[6]
J. H. Baron,et al.
Variation Between Observers in Describing Mucosal Appearances in Proctocolitis*
,
1964,
British medical journal.